Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

Saroglitazar Magnesium was launched in India during September 2013, under the brand name 'Lipaglyn', for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type 2 diabetes not controlled by statins.

New Delhi: Zydus Cadila on Friday said it has completed phase III clinical trial of Saroglitazar Mg, used for treating type 2 Diabetes, in India.

"The trial was a multi-centric, randomized, double-blind study to evaluate the safety and efficacy of 2mg and 4mg of Saroglitazar compared to Pioglitazone 45mg in patients with type 2 Diabetes Mellitus.

"The phase 3 trial enrolled 1,140 subjects and studied the patients over a period of 56 weeks," Zydus Cadila said in a statement.

Also Read: Patients with NASH have been enrolled in 3 phase III trials of Saroglitazar, says Zydus Cadila

Saroglitazar Magnesium was launched in India during September 2013, under the brand name 'Lipaglyn', for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type 2 diabetes not controlled by statins.

"Insulin resistance is the root cause of type 2 Diabetes Mellitus and the data from this trial reveals that Saroglitazar Mg, a next-generation Insulin Sensitizer without the edema and weight gain side effects, could emerge as a potent anti-diabetic agent for millions of patients suffering from type 2 diabetes," said Zydus group Chairman Pankaj R Patel.

Read Also: Zydus Cadila launches Ramelteon tablets in US to treat insomnia